The current Endoscopy IV study
—a validation of the use of our TRIAGE-concept in selection for diagnostic colonoscopy—thus, reducing the total number to only the necessary
The total budget for inclusion of study participants, collection of blood samples, recording subject-related data plus purchase of blood collection equipment, centrifuges, freezers etc. is about 15.8 million DKK.
Dedicated employees (research nurses, technicians, secretaries etc) are conducting the everyday research tasks.
The research unit at Hvidovre Hospital, under PI: Professor Hans Jørgen Nielsen coordinates, manages and raises the funding for our entire research.
The research study is a collaborative approach of surgical and biochemical departments at: Amager /Hvidovre, Bispebjerg, Herlev and Hillerød Hospitals in The Capital Region of Denmark.
The current Endoscopy III study
—a validation of a screening concept based on biomarkers in blood samples
The total budget for inclusion of all the study participants, collection of blood samples and recording of subject-related data plus purchase of blood collection equipment, centrifuges, freezers etc. is > 140 million DKK.
Dedicated employees—research nurses, technicians and secretaries—are conducting our research on a daily basis.
The research unit at Hvidovre Hospital under PI: Professor Hans Jørgen Nielsen, coordinates, manages and raises the funding for our entire research.
The research study is a collaborative approach of surgical and biochemical departments at: Amager /Hvidovre, Bispebjerg, Herlev, Herning, Hillerød, Holstebro, Horsens, Silkeborg, Randers and Viborg Hospitals
In additon to public and private Danish funds and companies
our research is, also, funded through commercial partnerships/sponsorship-agreements, which promote the results significantly.
Such collaborations lead to specific, external analyses of recently developed and implemented highly specific biological entities such as proteomics, genomics, epigenomics, transcriptomics and metabolomics—
the Danish clinical collaboration provides all the plasma, serum and buffy-coat samples plus the audited clinical data—all of which combined improves the entire blood-based screening concept.
Commercial contractual research and collaboration agreements introduce specific laboratory analyses and fundings to the study, which reduce otherwise requirements for external—private and/or govermental—grants and foundations.
Based on the signed contracts the entire study is headed by PI—Professor Hans Jørgen Nielsen, MD, DMSc—who also, referring the contracts, ensure that at least half of the primary IPR remains in Danish hands.
By June 2015 contracts we have signed contracts with:
Abbott Laboratories Inc., Chicago, USA • ChemImage inc., Pittsburgh PA, USA • Clinical Genomics Inc., Bridgewater, NJ, USA • DiscernDX Inc., San Francisco, CA, USA • EDP Biosciences Inc., Nashville, TN, USA • VolitionRX, Isnes, Belgium•
Three of these companies actively sponsor the Endoscopy III / PART 2 A-study:
the initial inclusion of the 30.000 entrants with data and blood samples.
Inclusion of the commercial collaborators secures that usable results will be commercialized and thereby implemented to clinical use—the research collaborative group in Denmark does not have sufficient capacity or economy to perform implementation without international collaboration with major commercial partners
Such collaborative approaches secure that achieved usable results may benefit subjects screened for intra-and/or extra-colonic neoplasia or even other cancerous malignanies.